Thursday links: the need for regulation

Prediction marketsKalshi is going to allow bets on drug trials. (theguardian.com)Kalshi is rolling out more features for institutional traders. (semafor.com)Trump's teleprompter operator reportedly has been betting on Kalshi on speech outcomes. (abcnews.com)FinanceThe Bloomberg Terminal is the still the market leader. (ft.com)Truth Social is now selling access to its API. (axios.com)PharmaNovo Nordisk ($NVO) is besting Eli Lilly ($LLY) in weight loss pills. (wsj.com)Eli Lilly ($LLY) is buying AtaiBeckley which is developing psychedelics for mental health treatment. (cnbc.com)Merck's ($MRK) cholesterol pill, Lipfendra, is a blockbuster in waiting. (biopharmadive.com)AIEverybody is converging on the need to regulate AI. (axios.com)Are AI executives uniquely at-risk of violence? (wsj.com)The Apple-OpenAI suit is going to involve a lot of e-mails. (spyglass.org)Stay in touchWork in wealth management? Sign up for our advisor-exclusive Talking Wealth newsletter. (talkingwealthpod.com)Don't